JPMorgan raised the firm’s price target on Cellebrite (CLBT) to $24 from $22 and keeps an Overweight rating on the shares. The firm updating security software price targets for 2025 to reflect its view of current and anticipated market conditions.
Education
About Us
Working with TipRanks
Follow Us
1